RTX001

DRUG2 trials

Conditions

Cirrhosis, DecompensatedCirrhosis, LiverDecompensated CirrhosisDecompensated Liver CirrhosisEnd-stage Liver Disease (ESLD)Fibrosis and Cirrhosis of LiverLiver CirrhosisLiver Diseases

Phase 1

An Open-label Phase 1/2 Multicentre Study to Evaluate the Safety, Tolerability and Efficacy of RTX001 Autologous Macrophages in Participants with Liver Cirrhosis who have Hepatic Decompensation (EMERALD)

RecruitingCTIS2024-516288-10-00

Resolution Therapeutics LimitedLiver Cirrhosis

Start: 2025-03-21Target: 8Updated: 2025-11-05

RTX001 Autologous Engineered Macrophages for Liver Cirrhosis

RecruitingNCT06823713

Resolution Therapeutics LimitedCirrhosis, Decompensated, Cirrhosis, Liver, Decompensated Cirrhosis +5

Start: 2024-10-15End: 2028-11-29Target: 30Updated: 2026-01-28

RTX001

Sponsors

Conditions

Phase 1